# A Study of IOV-5001 in Adults With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07743723/  
OnCo record `nct07743723` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Iovance Biotherapeutics, Inc., not yet recruiting.

## Summary

A Study of IOV-5001 in Adults With Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07743723 by Iovance Biotherapeutics, Inc., with a registry enrolment figure of 106 participants, started 2026-09 and due to reach its primary completion in 2034-03. Interventions recorded: IOV-5001. Conditions listed: Advanced Solid Tumors; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Solid Tumors; Unresectable Solid Tumor. Triple-negative eligibility wording from the registry: "TNBC: Participant has a histologically or pathologically confirmed diagnosis of unresectable or Stage IV breast cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07743723
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Multi-cohort, Open-label Study of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen With IOV-5001 in Participants With Previously Treated Advanced Solid Tumors
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 106

## Sources

- ClinicalTrials.gov NCT07743723: https://clinicaltrials.gov/study/NCT07743723

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07743723.json